Clinical Trial Update: ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update for ABC294640 (Opaganib) in refractory/relapsed multiple myeloma; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• ABC294640 (Opaganib) (opaganib)

Snippet

Sponsor: RedHill Biopharma Limited | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2021-06-18